Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)

Next Previous
Trial Profile

An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iclepertin (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Acronyms CONNEX; CONNEX-X
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 04 Apr 2025 Status changed from completed to discontinued. (Reason the study was stopped: Sponsor decision, project discontinued).
  • 20 Mar 2025 Status changed from active, no longer recruiting to completed.
  • 03 Mar 2025 Planned End Date changed from 18 Dec 2025 to 10 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top